CytomX Therapeutics (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.
At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications. In addition, the company is advancing CX-2009, a Probody drug conjugate targeting the transferrin receptor (CD71), as well as other Probody candidates addressing novel tumor-associated antigens. These programs seek to broaden the therapeutic window and enable new combinations in cancer treatment.
Founded in 2008 and headquartered in South San Francisco, California, CytomX completed its initial public offering on the Nasdaq stock exchange in 2014 under the ticker symbol CTMX. The company has established collaborations to support global clinical development and manufacturing, with trials conducted across North America and Europe. CytomX leverages its integrated discovery engine to generate and optimize masked antibody libraries, supporting both internal and partnered programs.
Led by President and Chief Executive Officer Tony Gregorio, Ph.D., CytomX Therapeutics draws on a team of scientific and clinical experts in antibody engineering, oncology drug development, and translational research. The company remains committed to advancing its Probody platform to deliver safer, more effective cancer therapies for patients worldwide.
